Format

Send to

Choose Destination
Aliment Pharmacol Ther. 2017 Jan;45(1):178-179. doi: 10.1111/apt.13842.

Editorial: adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease.

Author information

1
Department of Gastroenterology, Alfred Hospital and Monash University, Melbourne, Vic., Australia.
PMID:
27910149
DOI:
10.1111/apt.13842
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center